問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Urology

更新時間：2023-09-19

蔡育傑Tsai, Yu-Chieh
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

76Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡育傑

List

145Cases

2023-04-30 - 2026-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2022-01-05 - 2026-01-06

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-01-01 - 2031-12-31

Phase III

A Phase 3 Randomized, Open-label Study of MK‑5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy

  • Condition/Disease

    Prostate Cancer Metastatic

  • Test Drug

    MK-5684

Participate Sites
5Sites

Recruiting5Sites

2019-06-01 - 2024-07-31

Phase III

A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Carcinoma

  • Test Drug

    Lenvatinib Pembrolizumab

Participate Sites
7Sites

Recruiting7Sites

吳文正
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Urology

2014-10-01 - 2020-12-01

Phase III

A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer

  • Condition/Disease

    Recurrent or Progressive Metastatic Urothelial Cancer

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
5Sites

Terminated5Sites

2018-01-15 - 2019-08-21

Phase III

A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients Who Have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)

  • Condition/Disease

    Urothelial Cancer

  • Test Drug

    Pembrolizumab ; Epacadostat

Participate Sites
5Sites

Terminated5Sites

2018-01-15 - 2020-12-25

Phase III

A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) or Placebo in Participants With Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

  • Condition/Disease

    Urothelial Cancer

  • Test Drug

    Keytruda / Epacadostat

Participate Sites
6Sites

Terminated5Sites

2017-11-01 - 2022-06-27

Phase III

A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)

  • Condition/Disease

    Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC)

  • Test Drug

    Pembrolizumab; Epacadostat

Participate Sites
6Sites

Terminated6Sites

2015-04-15 - 2019-12-31

Phase II

A Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer

  • Condition/Disease

    Advanced/Unresectable or Metastatic Urothelial Cancer

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
3Sites

Terminated2Sites

2016-07-01 - 2020-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 10 11 12 13 14 15
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB